GT Biopharma
GTBP
47 hedge funds and large institutions have $9.28M invested in GT Biopharma in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 20 reducing their positions, and 12 closing their positions.
3,800% more call options, than puts
Call options by funds: $78K | Put options by funds: $2K
0.15% less ownership
Funds ownership: 0.49% → 0.34% (-0.15%)
18% less funds holding
Funds holding: 57 → 47 (-10)
28% less capital invested
Capital invested by funds: $12.9M → $9.28M (-$3.6M)
45% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 20
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$617K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$351K |
| 3 |
E
Ergoteles
New York
|
+$205K |
| 4 |
AWS
Atria Wealth Solutions
New York
|
+$148K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$64.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.96M |
| 2 |
State Street
Boston,
Massachusetts
|
-$979K |
| 3 |
Morgan Stanley
New York
|
-$336K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$315K |
| 5 |
Renaissance Technologies
New York
|
-$307K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
JP Morgan Chase
New York
| – | -$21K | -277 | -100% |
|
52
New York State Common Retirement Fund
Albany,
New York
| – | -$20.2K | -267 | -98% |
|
53
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| – | -$22K | -251 | Closed |
|
|
AB
54
Amalgamated Bank
New York
| – | -$9K | -99 | Closed |
|
55
Barclays
London,
United Kingdom
| – | -$8K | -96 | Closed |
|
|
AIP
56
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$5K | -62 | Closed |
|
57
Legal & General Group
London,
United Kingdom
| – | -$5K | -61 | Closed |
|
GTBP Hedge Fund Activity: Q2 2022 in Review
47 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2022, worth a combined $9.28M — down 28% from $12.9M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of GTBP and 4 opened new positions — a net loss of 8 holders — while 20 trimmed existing stakes and 11 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $617K. The largest seller was BlackRock, cutting an estimated $1.96M.
- 47 institutional investors held GT Biopharma (GTBP) as of Q2 2022, down from 57 in Q1 2022.
- Funds reported $9.28M of GT Biopharma stock for Q2 2022, down 28% quarter-over-quarter.
- 4 funds opened new GT Biopharma positions in Q2 2022 and 12 closed out, a net change of -8 holders.
- The largest GT Biopharma buyer in Q2 2022 was Millennium Management, an estimated $617K added.
- The largest GT Biopharma seller in Q2 2022 was BlackRock, an estimated $1.96M sold.
Based on aggregated 13F filings for Q2 2022.